Medical Molecular Morphology

, Volume 42, Issue 2, pp 128–131 | Cite as

The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma

  • Naoto Kuroda
  • Masahiko Ohara
  • Kaori Inoue
  • Keiko Mizuno
  • Nokiaki Fujishima
  • Nobumasa Hamaguchi
  • Gang-Hong Lee
Original Paper


Recently, the concept of basal-like carcinoma has been proposed. However, there are only a few reports about the relationship between triple-negative cancer and basal-like carcinoma. In this article, we report the study of the expression of basal cell markers in 11 triple-negative cancers. Eight tumors (4 metaplastic carcinomas, 2 invasive ductal carcinomas, 1 invasive papillary carcinoma, and 1 medullary carcinoma) were positive for more than three markers among cytokeratins 5, 14, and 17, and p63. Three tumors (2 invasive ductal carcinomas and 1 apocrine carcinoma) were completely negative for all markers. Among 8 tumors positive for basal markers, cytokeratins 5 and 17 were expressed in all 8 tumors, cytokeratin 14 in 6 tumors, and p63 in 7 tumors. Finally, we conclude that the majority of triple-negative cancer may correspond to basal-like carcinoma, but the two entities are not identical. The use of combination immunohistochemistry including cytokeratins 5, 14, and 17 and p63 may contribute to the detection of basal-like carcinoma.

Key words

Triple-negative cancer Basal-like carcinoma Immunohistochemistry 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Foulkes WD, Stefannsson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482–1485PubMedGoogle Scholar
  2. 2.
    Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET (2003) Breast cancer classification and progenosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100: 10393–10398PubMedCrossRefGoogle Scholar
  3. 3.
    Rakha EA, El-Sayed ME, Reis-Filho JS, Ellis IO (2008) Expression profiling technology: its contribution to our understanding of breast cancer. Histopathology (Oxf) 52:67–81Google Scholar
  4. 4.
    Payne SJL, Bowen RL, Lones JL, Wells CA (2008) Predictive markers in breast cancer: the present. Histopathology (Oxf) 52: 82–90CrossRefGoogle Scholar
  5. 5.
    Faratian D, Bartlett J (2008) Predictive markers in breast cancer: the future. Histopathology (Oxf) 52:91–98Google Scholar
  6. 6.
    Jones C, Ford E, Gillett C, Ryder K, Merrett S, Reis-Filho JS, Fulford LG, Hanby A, Lakhani SR (2004) Molecular cytogenetic identification of subgroups of Grade III invasive ductal breast carcinomas with different clinical outcomes. Clin Cancer Res 10: 5988–5997PubMedCrossRefGoogle Scholar
  7. 7.
    Arnes JB, Brunet JS, Stefansson I, Begin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD (2005) Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 11:4003–4011PubMedCrossRefGoogle Scholar
  8. 8.
    Ribeiro-Silva A, Ramalho LNZ, Garcia SB, Brandao DF, Chahud F, Zucoloto S (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology (Oxf) 47:458–466CrossRefGoogle Scholar
  9. 9.
    Tsuda H, Morita D, Kimura M, Shinto E, Ohtsuka Y, Matsubara O, Inazawa J, Tamaki K, Mochizuki H, Tamai S, Hiraide H (2005) Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci 96:48–53PubMedGoogle Scholar
  10. 10.
    Leibl S, Gogg-Kammerer M, Sommersacher A, Denk H, Maoinfar F (2005) Metaplastic breast carcinomas: are they of myoepithelial differentiation? Immunohistochemical prolife of the sarcomatoid subtype using novel myoepithelial markers. Am J Surg Pathol 29:347–353PubMedCrossRefGoogle Scholar
  11. 11.
    Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhan SR, Hanby A (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology (Oxf) 49:22–34CrossRefGoogle Scholar
  12. 12.
    Shien T, Tashiro T, Omatsu M, Matsuda T, Furuta K, Sato N, Akashi-Tanaka S, Uehara M, Iwamoto E, Kinoshita T, Fukutomi T, Tsuda H, Hasegawa T (2006) Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation. J Clin Pathol 58:1299–1304CrossRefGoogle Scholar
  13. 13.
    Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her 2/neuoverexpressing phenotypes. Hum Pathol 37:1217–1226PubMedCrossRefGoogle Scholar
  14. 14.
    Fadare O, Tavassoli FA (2007) The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol 14: 358–373PubMedCrossRefGoogle Scholar
  15. 15.
    Fadare O, Yeh IT (2007) Basal-like breast cancers. Pathol Case Rev 12:143–153CrossRefGoogle Scholar
  16. 16.
    Diaz LK, Cryns VL, Symmans F, Sneige N (2007) Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 14:419–430PubMedCrossRefGoogle Scholar
  17. 17.
    Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology (Oxf) 52:108–118CrossRefGoogle Scholar
  18. 18.
    Tavassoli FA, Devilee P (eds) Tumours of the breast and female genital organs. World Health Organization classification of tumours. IARC Press, Lyon, pp 10–80Google Scholar
  19. 19.
    Kuroda N, Fujishima N, Inoue K, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Lee GH (2008) Basal-like carcinoma of the breast: further evidence of the possibility that most metaplastic carcinomas may be actually basal-like carcinoma. Med Mol Morphol 41:117–120PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society for Clinical Molecular Morphology 2009

Authors and Affiliations

  • Naoto Kuroda
    • 1
  • Masahiko Ohara
    • 1
  • Kaori Inoue
    • 1
  • Keiko Mizuno
    • 1
  • Nokiaki Fujishima
    • 2
  • Nobumasa Hamaguchi
    • 2
  • Gang-Hong Lee
    • 3
  1. 1.Department of Diagnostic PathologyKochi Red Cross HospitalKochiJapan
  2. 2.Department of SurgeryKochi Red Cross HospitalKochiJapan
  3. 3.Department of Pathology, Kochi Medical SchoolKochi UniversityKochiJapan

Personalised recommendations